EE649 Cost Per Responder of Bimekizumab Against Il-17A, IL-12/23 and IL-23 Inhibitors in the Treatment of Psoriatic Arthritis in Sweden
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.914
https://www.valueinhealthjournal.com/article/S1098-3015(23)04044-5/fulltext
Title :
EE649 Cost Per Responder of Bimekizumab Against Il-17A, IL-12/23 and IL-23 Inhibitors in the Treatment of Psoriatic Arthritis in Sweden
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04044-5&doi=10.1016/j.jval.2023.09.914
First page :
Section Title :
Open access? :
No
Section Order :
10404